Brief: Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint
19/03/2025 12:24
March 19 (Reuters) - Roivant Sciences Ltd ROIV.O: ROIVANT ANNOUNCES POSITIVE RESULTS FOR BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) STUDIES ROIVANT SCIENCES LTD - PHASE 3 MG STUDY MEETS PRIMARY ENDPOINT WITH 5.6 POINT IMPROVEMENT Source text: ID:nGNX81VgfG Further company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple